58 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
into the LPC Purchase Agreement, the Company issued 230,414 shares of common stock to Lincoln Park as an initial commitment fee. Upon execution of the LPC
8-K
EX-99.1
yr7vm
3 Aug 23
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
4:41pm
8-K
EX-99.2
shu0 cclhrpk98y
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
EX-99.1
yrq gil6ph
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm
8-K
gbnzxdkzmr2i db
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
lff9ifrqqct
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-10.1
xfg9z
9 Feb 22
Entry into a Material Definitive Agreement
4:10pm
8-K
yk7 x4mzgbb92z5
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
ekcr0s7a0dhwr
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.2
7lj61xa6668r ou
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-5.1
2yy7b2
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
424B5
u2v101l4 un
14 Jan 22
Prospectus supplement for primary offering
4:37pm